Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Smith & Nephew breaks into new woundcare segment with BlueSky buy

This article was originally published in Clinica

Executive Summary

UK medical device multinational Smith & Nephew is to boost its advanced wound care division with the acquisition of BlueSky Medical, a privately-held, US company operating in the $1.2bn negative pressure wound therapy (NPWT) market.

You may also be interested in...



Smith & Nephew Publishes Meta-Analysis Suggesting PICO's Wound Therapy Reduces Surgical Site Infections

Smith & Nephew's meta-analysis of 16 peer-reviewed publications shows prophylactic application of the company's PICO Negative Pressure Wound Therapy System reduces surgical site infections by 58% and wound rupturing along the surgical incision by 26%, while cutting the average hospital stay by a half day.

Market Intel: Intense Competition, Innovation Drive Healing Trends In Wound Care

The global advanced wound-care market is expected to reach $10.4bn by 2020, driven by massive competition, and forcing companies to innovate constantly to address the rising prevalence of chronic wound injuries, diabetic foot ulcers and burns. While regulatory and reimbursement challenges prevail, opportunities in this highly segmented market, in particular, in the advanced wound-dressings sector, are vast, with double-digit revenue growth potential.

ASA Finds 'Irresponsible' Weight Loss Ad Difficult To Stomach

Vision Healthcare’s Sensilab pulled Facebook advertisements for its weight loss supplements after UK regulator the Advertising Standards Authority launched an investigation into whether the marketing, which featured slim models, was "irresponsible." 

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT048378

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel